Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis

被引:45
作者
Tellez-Avila, Felix I. [1 ]
Sanchez-Avila, Francisco [1 ]
Garcia-Saenz-de-Sicilia, Mauricio [1 ]
Chavez-Tapia, Norberto C. [1 ]
Franco-Guzman, Ada M. [1 ]
Lopez-Arce, Gustavo [1 ]
Cerda-Contreras, Eduardo [1 ]
Uribe, Misael [1 ]
机构
[1] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Gastroenterol, Secc 16, Mexico City 14000, DF, Mexico
关键词
cryptogenic chronic hepatitis; metabolic syndrome; obesity; diabetes mellitus;
D O I
10.3748/wjg.14.4771
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To evaluate the prevalence of metabolic syndrome (MS), obesity and type 2 diabetes mellitus (T2DM) in a group of Mexican Mestizo patients with cryptogenic cirrhosis (CC) and to compare this group with patients with cirrhosis secondary to other causes (disease controls). METHODS: Patients with CC, diagnosed between January, 1990 and April, 2005, were included in a retrospective study. Patients with cirrhosis caused by chronic hepatitis C, alcohol abuse or autoimmune hepatitis (AIH) served as disease controls. RESULTS: A total of 134 patients with CC were analyzed. Disease controls consisted of 81 patients with chronic hepatitis C, 33 with alcohol abuse and 20 with AIH. The median age of patients with CC was 57 years (range, 16-87); 83 (61.9%) patients were female; 53 (39.6%) were Child A, 65 (48.5%) Child B, and 16 (11.9%) were Child C cirrhosis. The prevalence of MS (29.1% vs 6%; P < 0.001), obesity (16.4% vs 8.2%; P = 0.04) and T2DM (40% vs 22.4%; P = 0.013) was higher in CC patients than in disease controls. There were no differences in sex, age or liver function tests between the two groups. CONCLUSION: The prevalence of MS, obesity and T2DM were higher in patients with CC than in patients with cirrhosis secondary to others causes. Our findings support the hypothesis that non-alcoholic steatohepatitis (NASH) plays an under-recognized role in CC. (C) 2008 The WJG Press. All rights reserved.
引用
收藏
页码:4771 / 4775
页数:5
相关论文
共 24 条
[1]   High prevalence of metabolic syndrome in Mexico [J].
Aguilar-Salinas, CA ;
Rojas, R ;
Gómez-Pérez, FJ ;
Valles, V ;
Ríos-Torres, JM ;
Franco, A ;
Olaiz, G ;
Rull, JA ;
Sepúlveda, J .
ARCHIVES OF MEDICAL RESEARCH, 2004, 35 (01) :76-81
[2]   RISK-FACTORS FOR ACUTE NON-A, NON-B HEPATITIS IN THE UNITED-STATES AND ASSOCIATION WITH HEPATITIS-C VIRUS-INFECTION [J].
ALTER, MJ ;
HADLER, SC ;
JUDSON, FN ;
MARES, A ;
ALEXANDER, WJ ;
HU, PY ;
MILLER, JK ;
MOYER, LA ;
FIELDS, HA ;
BRADLEY, DW ;
MARGOLIS, HS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 264 (17) :2231-2235
[3]   Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis [J].
Angulo, P ;
Keach, JC ;
Batts, KP ;
Lindor, KD .
HEPATOLOGY, 1999, 30 (06) :1356-1362
[4]  
Angulo Paul, 2005, Rev Gastroenterol Mex, V70 Suppl 3, P52
[5]   Cryptogenic cirrhosis: Clinicopathologic findings at and after liver transplantation [J].
Ayata, G ;
Gordon, FD ;
Lewis, D ;
Pomfret, E ;
Pomposelli, JJ ;
Jenkins, RL ;
Khettry, U .
HUMAN PATHOLOGY, 2002, 33 (11) :1098-1104
[6]   NONALCOHOLIC STEATOHEPATITIS - AN EXPANDED CLINICAL ENTITY [J].
BACON, BR ;
FARAHVASH, MJ ;
JANNEY, CG ;
NEUSCHWANDERTETRI, BA .
GASTROENTEROLOGY, 1994, 107 (04) :1103-1109
[7]   Distinct enzyme profiles in patients with cryptogenic cirrhosis reflect heterogeneous causes with different transplantation (OLT):: A long-term documentation before and after OLT [J].
Berg, T ;
Neuhaus, R ;
Klein, R ;
Leder, K ;
Lobeck, H ;
Beckstein, WO ;
Müller, AR ;
Wiedenmann, B ;
Hopf, U ;
Berg, PA ;
Neuhaus, P .
TRANSPLANTATION, 2002, 74 (06) :792-798
[8]   DIABETES MELLITUS AND CIRRHOSIS OF LIVER [J].
BLOODWORTH, J .
ARCHIVES OF INTERNAL MEDICINE, 1961, 108 (05) :695-&
[9]   Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease [J].
Caldwell, SH ;
Oelsner, DH ;
Iezzoni, JC ;
Hespenheide, EE ;
Battle, EH ;
Driscoll, CJ .
HEPATOLOGY, 1999, 29 (03) :664-669
[10]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497